$HIMS News

HIMS Stock Eyes 2-Week Green Streak: Analyst Sees Nearly 20% Upside On Multi-Year Opportunity In Peptides

Taking A Fresh Look At Hims & Hers Health (HIMS) Valuation After Recent Share Price Swings

Political Scrutiny Tests Hims And Hers GLP1 Weight Loss Growth Story

HIMS Stock Slips Despite Early Eucalyptus Buyout Close: Analyst Sees 10% Downside On GLP-1 Profit Risks

Hims & Hers Expands With Eucalyptus Acquisition

Hims And Hers Health Expands With Eucalyptus Acquisition And Global Growth Prospects

Hims & Hers Completes Acquisition of Eucalyptus, Expanding Access to Comprehensive, Clinically-Backed Weight Management Care in Germany

Hims & Hers Completes Acquisition of Eucalyptus, Parent Company of Juniper, Officially Entering Japanese Market

Hims & Hers Completes Acquisition of Eucalyptus, Accelerating Its Push to Transform Healthcare for Canadians

Hims & Hers Completes Acquisition of Eucalyptus, Advancing its Position as the World’s Largest Consumer Health Platform

Hims & Hers Completes Acquisition of Eucalyptus, Advancing Position as the World's Largest Consumer Health Platform

Hims & Hers Expands Integrated Health Access via Platform Expansion

Hims And Hers Canadian GLP 1 Push Tests Broader Wellness Subscription Thesis

HIMS Stock Eyes Breakout Week: Eight New Partners Fuel Push To Build An All-In-One Health Platform

Hims & Hers Stock Spikes -- Insider Sends Strong Signal With $1 Million Buy

Hims & Hers Gains 5% on Insider Buying

HIMS vs. TEM: Which AI Healthcare Stock Offers Better Upside Now?

Hims & Hers Shares Rally On Million-Dollar Insider Purchase

Hims & Hers Health Form4 Filing Shows David Wells Bought 48,400 Shares At An Average Price Of $24.23/Share

Hims & Hers faces steep climb to hit 2026 guidance as Wegovy churn risk looms, says BofA